Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: Use of CD44 as an aid in early diagnosis
Article first published online: 21 AUG 2002
Copyright © 2002 Wiley-Liss, Inc.
Volume 50, Issue 4, pages 225–230, 15 August 2002
How to Cite
Karmon, Y., Manaster, J. and Chezar, J. (2002), Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: Use of CD44 as an aid in early diagnosis. Cytometry, 50: 225–230. doi: 10.1002/cyto.10110
- Issue published online: 26 DEC 2002
- Article first published online: 21 AUG 2002
- Manuscript Accepted: 25 MAR 2002
- Manuscript Received: 17 APR 2001
- myelodysplastic syndromes;
- flow cytometry;
- bone marrow
We investigated the possibility that myeloid cells from the bone marrow (BM) of myelodysplastic patients differ in their expression of CD44 antigen compared with expression of the antigen in normal controls. In addition, two triple-surface marker assays incorporating, respectively, CD44/CD33/CD66 and CD33/CD34/HLA-DR were used to evaluate the degree of myeloid maturation and assess the number of blasts in BM by flow cytometry. Patients with early-stage myelodysplastic syndrome (MDS; RA [FAB classification]) have significantly decreased expression of CD44 on gated myeloid cells. In contrast, patients with late-stage MDS (RAEB and RAEB-T [FAB classification]) showed an elevated expression of CD44 and an increased number of CD34 blasts compared with early-stage MDS patients and normal controls. Late-stage MDS patients also had an increase in the immature myeloid compartment (CD66 weak expression) compared with early-stage MDS patients and normal controls. We have already included this assay as part of our MDS evaluation protocol alongside BM morphology and cytogenetics. Cytometry (Clin. Cytometry) 50:225–230, 2002. © 2002 Wiley-Liss, Inc.